findmyKOL

Lisa Carey, MD

Enriched profile

L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research; Deputy Director for Clinical Sciences, UNC Lineberger Comprehensive Cancer Center · University of North Carolina at Chapel Hill

ORCIDNPI
Region🇺🇸 Chapel Hill, NC · Southeast · United StatesSpecialtyHematology / OncologyFocusBreast Cancer Treatment Studies+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2000–2026

Lisa Carey is L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research; Deputy Director for Clinical Sciences, UNC Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill. OpenAlex indexes 987 publications with 54,947 citations (h-index 105); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Lisa Carey, MD, is L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research at University of North Carolina at Chapel Hill, School of Medicine / UNC Lineberger Comprehensive Cancer Center. The public record shows 987 publications with 54,947 citations (h-index 105), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 9 companies, 8 NIH-funded awards (2000–2026).

  • Most recent indexed publication: 2026 · Molecular cancer therapeutics
  • Top research focus: Breast Cancer Treatment Studies
  • 15 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 9 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer12 trialsSarcoidosis1 trialSarcoidosis, Pulmonary1 trialIdiopathic Pulmonary Fibrosis1 trialLung Diseases, Interstitial1 trial

Research focus

OpenAlex concept fingerprint
Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyCancer Genomics and Diagnostics

Drugs & molecules

across trials, industry payments and publications
Enhertugeneric · TrastuzumabClinical trialsIndustry payments1Publications7Ibrancegeneric · PalbociclibClinical trialsIndustry payments5Publications2Trodelvygeneric · SacituzumabClinical trialsIndustry payments1Publications6

Works with

trial sponsors and companies reporting payments
UNC Lineberger Comprehensive Cancer CenterClinical trials11Industry paymentsPfizer Inc.Clinical trialsIndustry payments9AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments8

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
987publications

Distinct works indexed by OpenAlex, matched via ORCID; 67 in PubMed.

54,947citations

Total citations across indexed works.

105h-index

Hirsch index (OpenAlex). i10-index 365.

Clinical & industry

trials, payments and federal funding
15clinical trials

Investigator role on registered studies.

View trials
9companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
8NIH grants · 2000–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    83.2%
    Aromatase Inhibitor62.1%
    Letrozole77%Anastrozole23%
    Part D<11 patients
    Kinase inhibitor12.1%
    Kisqali54%Ibrance46%
    Part D<11 patients
  • Nervous system

    11.2%
    SNRI5.6%
    Duloxetine Hcl100%
    Part D<11 patients
    Gabapentinoids5.6%
    Gabapentin100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    5.6%
    Serotonin-3 Receptor Antagonist5.6%
    Ondansetron Hcl100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

8 NIH research awards on record, funded 20002026 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

176 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Charles M. Perou281Eric P. Winer169Hope S. Rugo120

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    opmed.doximity.com/authors/lisa-a-carey-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →opmed.doximity.com
  • Doximity

    doximity.com/pub/lisa-carey-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/lisa-carey-83583441

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
1 more verified account behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/unchealthcare/posts/dr-lisa-carey-of-unc-lineberger-comprehensive-cancer-center-is-the-only-breast-c/3767170573295080

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
  • Facebook

    facebook.com/unchealthcare/videos/unc-lineberger-cancer-researcher-dr-lisa-carey-on-wral-tv/3066522313422325

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
  • Facebook

    facebook.com/unclineberger/posts/unc-linebergers-lisa-carey-md-scm-fasco-will-lead-the-development-of-a-next-gene/1331063065695659

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
6 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • FASCO

    Fellow of the American Society of Clinical Oncology, 2019-present

    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • BA

    Wellesley College

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • MD

    Johns Hopkins University School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • ScM (MS)

    Johns Hopkins Bloomberg School of Public Health

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • Residency and fellowship

    Johns Hopkins Hospital (internal medicine / medical oncology)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu

Editorial & leadership roles

journal and society appointments
  • Inaugural Director

    UNC Center for Triple Negative Breast Cancer

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unclineberger.org
  • Member

    Board of Directors, American Society of Clinical Oncology (ASCO), 2020-present

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu
  • Former Chief

    Division of Hematology/Oncology and Physician-in-Chief, N.C. Cancer Hospital

    2020
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org
4 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
2 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.